Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p79
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 79/312)
Character Range: 15938636–15949531

14857
                                                                                                                           Continuing treatment
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must have previously received PBS-subsidised treatment with this drug for this condition.
C14868              P14868         CN14868          Cyproterone                                                            Moderate to severe androgenisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 14868
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           The condition must not be indicated by acne alone, as this is not a sufficient indication of androgenisation;
                                                                                                                           Patient must be female;
                                                                                                                           Patient must not be pregnant.
C14872              P14872         CN14872          Lanthanum                                                              Hyperphosphataemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 14872
                                                                                                                           Maintenance following initiation and stabilisation
                                                    Sevelamer                                                              The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           The condition must not be adequately controlled by calcium; AND
                                                    Sucroferric oxyhydroxide                                               Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; or
                                                                                                                           The condition must be where a serum calcium times phosphate product is greater than 4 at the commencement of therapy; AND
                                                                                                                           The treatment must not be used in combination with any other non-calcium phosphate binding agents; AND
                                                                                                                           Patient must be undergoing dialysis for chronic kidney disease.
C14874              P14874         CN14874          Sodium acid phosphate                                                  Hypophosphataemic rickets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Compliance with Authority Required procedures - Streamlined Authority Code 14874
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
C14883              P14883         CN14883          Tiagabine                                                              Partial epileptic seizures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures - Streamlined Authority Code 14883
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                    Zonisamide                                                             The condition must have failed to be controlled satisfactorily by other anti-epileptic drugs.

C14895              P14895         CN14895          Anastrozole                                                            Breast cancer
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                    Exemestane                                                             The condition must be hormone receptor positive.

                                                    Letrozole

                                                    Tamoxifen

C14898              P14898         CN14898          Alendronic acid with colecalciferol                                    Osteoporosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Compliance with Authority Required procedures - Streamlined Authority Code 14898
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient;
                                                                                                                           Patient must be aged 70 years or older;
                                                                                                                           Patient must have a Bone Mineral Density (BMD) T-score of -2.5 or less; AND
                                                                                                                           Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition.
                                                                                                                           The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in